What Deep Breath Intelligence does

Deep Breath Intelligence AG is a privately held Swiss MedTech company headquartered in Rotkreuz, Switzerland, founded in 2018 (originally as Deep Breath Initiative AG and rebranded in 2020). The company develops and commercializes an integrated breath-metabolomics platform that combines proprietary breath-collection hardware with secondary electrospray ionization (Super-SESI) coupled to Orbitrap high-resolution mass spectrometry and proprietary machine-learning analytics, targeting non-invasive diagnostics and therapeutic drug monitoring for healthcare providers, clinical laboratories, academic researchers, and pharmaceutical companies. Its current product portfolio spans four CE-marked/IVDR components — the DBI-BreathCollector (multi-layer breath sampling bag, IVDR-certified in 2024), DBI-BreathInjector (programmable injection device), SESI Adapter (sample transfer accessory), and DBI-EPIbreath (CE-IVD-certified software for real-time, non-invasive valproic-acid therapeutic drug monitoring in epilepsy) — alongside a separate Research-Edition BreathCollector and modular four-phase Contract Research Services for academic and pharma clients. DBI's newest line, DBI-CorBreath, extends the platform into decentralized chronic disease monitoring following a 2024 strategic pivot.

The company monetizes through three streams: (1) hardware sales of CE IVDR-marked BreathCollector kits (StarterKit-10 and SupremeKit-40 bundles) and precision injection/transfer instruments; (2) recurring/subscription software revenue from DBI-EPIbreath once commercialized (currently pre-launch); and (3) modular professional services revenue from contract research engagements structured around study setup, raw-data pre-processing, post-processing analysis, and advanced ML-driven analytics. Go-to-market is enterprise-direct, with no public pricing — buyers (hospitals, labs, academic centers, pharma companies) request quotes via the dbi.ch contact channel — and customer development is anchored by a sequence of named strategic collaborations with AstraZeneca (2023), Bayer (2022), GSK (2021), Löwenstein (2021), and UKBB (2019), supported by ecosystem partnerships with Microsoft for Startups, Innosuisse, Swissnex, Mindfuel, and Immanuel Albertinen Diakonie.

Name

Deep Breath Intelligence

Legal name

Deep Breath Intelligence AG

Website

https://dbi.ch

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Deep Breath Intelligence AG is a Swiss MedTech company that develops non-invasive breath-analysis hardware and machine-learning software for clinical diagnostics, therapeutic drug monitoring, and pharmaceutical research, serving hospitals, clinical laboratories, academic institutions, and pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Breath Analysis Diagnostics

NAICS

Custom Computer Programming Services (541511)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Pulmonary Function Testing (PFT) & Respiratory Diagnostics (HLAKANAC)

akta.pro secondary industry

Respiratory & Sleep RPM (COPD, asthma, sleep apnea) (HLALAFAB)

Keywords

• Breath analysis diagnostics
• Mass spectrometry platforms
• Therapeutic drug monitoring
• Breath metabolomics research
• Medical device manufacturing

Headquarters

HQ city

Rotkreuz

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales (BreathCollector, BreathInjector, SESI Adapter): Sale of CE IVDR-marked breath collection and analysis hardware products. Available in starter and supreme kit configurations with accessories.
2. Therapeutic Drug Monitoring Software (EPIbreath): SaaS/software solution for non-invasive therapeutic drug monitoring. Currently not commercially available; evaluating product implementation with clinics.
3. Contract Research Services: Modular four-phase research service supporting academic and clinical research: study design consulting, hands-on training, data acquisition, pre-processing, statistical analysis, ML-driven pattern recognition, and biological interpretation.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Deep Breath Intelligence develops and sells an integrated breath analysis platform for medical research and clinical practice. Its commercial offerings include CE-marked medical hardware (DBI-BreathCollector, DBI-BreathInjector, SESI Adapter) for exhaled breath sample collection and injection, a CE-IVD-certified therapeutic drug monitoring software (DBI-EPIbreath) for epilepsy, and modular contract research services covering study design, data acquisition, pre-processing, and ML-driven analytics using SESI-HRMS technology.

Product overview

Deep Breath Intelligence offers a portfolio of medical devices, instruments, and software for breath metabolomics analysis. The product line includes: DBI-BreathCollector (IVDR and Research editions) — multi-layer breath bags for sample collection; DBI-BreathInjector — precision injection device; SESI Adapter — sample transfer accessory; DBI-EPIbreath — therapeutic drug monitoring software (CE-IVD certified); and Contract Research services. These products form an integrated workflow: breath collection via BreathCollector, controlled injection via BreathInjector, sample transfer via SESI Adapter to the SESI-HRMS analytical platform, with ML-driven data analysis and therapeutic guidance via DBI-EPIbreath.

Differentiator

Problem solved

Functional benefit

Products and services

• DBI-BreathCollector IVDR CE IVDR-marked innovative non-sterile multi-layer breath bag designed for reliable collection, storage, and shipment of exhaled breath gases, optimized for downstream HRMS analysis. Available in STARTERKIT-10 (10 collectors + shipping boxes) and SUPREMEKIT-40 (4 starter kits + 40 mouthpieces) bundles for clinical and laboratory use.
• DBI-BreathInjector High-precision device engineered for controlled injection of exhaled breath gases into analytical platforms. Fully compatible with DBI-BreathCollector and programmable for specific injection requirements.
• SESI Adapter Accessory engineered for seamless sample transfer from DBI-BreathCollector to analytical devices, with smart design that pierces sealing caps effortlessly for airtight delivery.
• DBI-BreathCollector Research Lower-cost academic research bundle edition of DBI-BreathCollector offering the same smart design and performance, exclusively for research use including feasibility studies, method development, and academic investigations. Not CE marked (IVDR).
• Contract Research Modular breath analysis research service delivered in four phases: Phase 1 Study Setup & Data Acquisition (expert consulting, hands-on training, SOPs, QC software installation), Phase 2 Data Pre-Processing (raw data pipeline), Phase 3 Post-processing Analysis (statistics, visualization), Phase 4 Advanced Analytics (multivariate statistics, ML pattern recognition, biological identification). Targets academic institutions, clinical research organizations, and pharmaceutical companies.
• DBI-EPIbreath World's first IVD-certified software for non-invasive, real-time therapeutic drug monitoring via breath analysis. Uses machine learning to estimate systemic concentrations of valproic acid (VPA) and assesses seizure and side effect risks in epilepsy care. Not currently commercially available; being evaluated for clinical implementation with clinics.

Quantifiable outcome

• Results delivered within 10 minutes
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• Microsoft for StartupsminorGTM or Marketing Partner · 1 January 2025Partner logo displayed on DBI website indicating technology/marketing partnership through Microsoft for Startups program.
• MindfuelminorStrategic or Co-development Partner · 1 January 2025Swiss science education and innovation foundation partner logo displayed on website.
• SwissnexminorGTM or Marketing Partner · 1 January 2025Swiss global network connecting academia and business partner logo displayed. Swissnex supports international expansion and partnerships.
• Immanuel Albertinen DiakonieminorStrategic or Co-development Partner · 1 January 2025German healthcare provider partner logo displayed indicating potential clinical collaboration.
• AstraZenecacoreStrategic or Co-development Partner · 1 January 2023Strategic collaboration initiated in 2023 for breath analysis applications in pharmaceutical development. Leverages DBI's breath metabolomics platform for drug development research.
• BayercoreStrategic or Co-development Partner · 1 January 2022Collaboration in 2022 focused on DBI-Epibreath therapeutic drug monitoring software development and validation for clinical use.
• GSKcoreStrategic or Co-development Partner · 1 January 2021Collaboration started in 2021 for breath research applications in respiratory and pharmaceutical research.
• UKBB (University Children's Hospital Basel)coreStrategic or Co-development Partner · 1 January 2019Provided two SESI-HRMS platforms to UKBB in 2019 for pediatric breath analysis research.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Owlstone Medical: Owlstone Medical is the most direct competitor in breath-based disease detection and biomarker discovery, developing the Breath Biopsy platform for non-invasive diagnostics. Both companies focus on exhaled breath analysis for clinical research, pharma partnerships, and early disease detection.
• Spirosure (CAIRE Diagnostics): CAIRE Diagnostics (formerly Spirosure) develops fractional exhaled nitric oxide (FeNO) measurement devices for respiratory disease diagnosis and management. They share DBI's focus on non-invasive breath-based respiratory diagnostics for clinical use.
• Bedfont Scientific: Bedfont Scientific manufactures breath analysis monitors (Smokerlyzer, ToxCO, GastroCH4ECK) for medical and research use. They compete in the broader breath analysis device market with established products and global distribution.

Broad incumbents

• Bosch Healthcare Solutions: Bosch Healthcare Solutions develops breath analysis diagnostic devices (e.g., BreathSpec) for clinical use, leveraging Bosch's broader instrumentation portfolio. They are an incumbent medtech entrant in the same breath diagnostics category as DBI.
• ResMed: ResMed is a global leader in respiratory and sleep medicine devices, with growing interest in connected health and non-invasive monitoring. As a broad incumbent, they could expand into the breath analysis monitoring category where DBI plays.

Emerging players

• Breathomix: Breathomix is a Dutch spin-off developing eNose-based breath analysis for lung disease diagnosis, including COPD and lung cancer. They represent an emerging competitor in the same clinical breath diagnostics space as DBI.
• Mensia Technologies: Mensia Technologies (formerly Aryballe Technologies spin-off) develops digital olfaction and breath analysis solutions combining biosensors with AI. They overlap with DBI in using AI/ML for breath signal interpretation, though with hardware sensor rather than mass spectrometry approach.

Others

• Thermo Fisher Scientific: Thermo Fisher Scientific supplies the Q Exactive Plus Orbitrap HRMS that underpins DBI's SESI-HRMS platform. As the mass spectrometry incumbent and supplier, they are an ecosystem partner rather than direct competitor, but their strategic moves in clinical diagnostics shape DBI's runway.
• Fossiliontech: Fossiliontech supplies Super-SESI and Exhalion ionization technology used in DBI's SESI-HRMS platform. They are a critical technology supplier/partner and could be considered an enabling ecosystem participant.

Regional players

• Nox Medical: Nox Medical develops sleep diagnostics and respiratory monitoring devices. They are DBI's partner (via Löwenstein collaboration) and operate in adjacent respiratory diagnostics space with focus on sleep-disordered breathing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@deepbreathintelligence
• LinkedInlinkedin.com/company/deep-breath-intelligence
• Xx.com/the_dbi
• Facebookfacebook.com/thedbi

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deep Breath Intelligence